FORM 6-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
For the month ended
  
Commission File Number
November 2005
  
1-32608
 
 
VIREXX MEDICAL CORP.
(Translation of registrant's name into English)
 
8223 Roper Road NW, Edmonton, Alberta, Canada T6E 6S4
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F x     Form 40-F o
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
 
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes o No x
 
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ____
 
 
 
 
 
EXHIBIT LIST
 
Exhibit
Description
   
99.1 News Release
(ViRexx Announces Resignation of Rob Salmon)
   
99.2 News Release
(ViRexx To Present At Rodman & Renshaw Techvest Seventh Annual Healthcare Conference)
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
     
 
VIREXX MEDICAL CORP. 
 
 		  
 		  
 
Dated: November 8, 2005 By:  
/s/Marc Canton
 
Marc Canton, President